Literature DB >> 20170842

Current practice and future directions in the prevention and acute management of migraine.

Peter J Goadsby1, Till Sprenger.   

Abstract

Migraine is a common and disabling brain disorder with a strong inherited component. Because patients with migraine have severe and disabling attacks usually of headache with other symptoms of sensory disturbance (eg, light and sound sensitivity), medical treatment is often required. Patients can be managed by use of acute attack therapies (eg, simple analgesics or non-steroidal anti-inflammatory drugs) or specific agents with vasoconstrictor properties (ie, triptans or ergot derivatives). Future non-vasoconstrictor approaches include calcitonin gene-related peptide receptor antagonists. Preventive therapy is probably indicated in about a third of patients with migraine, and a broad range of pharmaceutical and non-pharmaceutical options exist. Medication overuse is an important concern in migraine therapeutics and needs to be identified and managed. In most patients, migraine can be improved with careful attention to the details of therapy, and in those for whom it cannot, neuromodulation approaches, such as occipital nerve stimulation, are currently being actively studied and offer much promise. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170842     DOI: 10.1016/S1474-4422(10)70005-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  63 in total

1.  Direct costs of preventive headache treatments: comparison of behavioral and pharmacologic approaches.

Authors:  Allison M Schafer; Jeanetta C Rains; Donald B Penzien; Leanne Groban; Todd A Smitherman; Timothy T Houle
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.

Authors:  Georgia Tsaousi; Chryssa Pourzitaki; Spyridon Siafis; Athanassios Kyrgidis; Vasilios Grosomanidis; Dimitrios Kouvelas; Georgios Papazisis
Journal:  Eur J Clin Pharmacol       Date:  2019-11-25       Impact factor: 2.953

Review 3.  [Psychological therapy of migraine: systematic review].

Authors:  G Fritsche; B Kröner-Herwig; P Kropp; U Niederberger; G Haag
Journal:  Schmerz       Date:  2013-06       Impact factor: 1.107

4.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

5.  New targets for migraine therapy.

Authors:  Amy R Tso; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

Review 6.  Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.

Authors:  János Tajti; Délia Szok; Anett Csáti; László Vécsei
Journal:  Curr Pain Headache Rep       Date:  2016-01

7.  Sex-, Stress-, and Sympathetic Post-Ganglionic Neuron-Dependent Changes in the Expression of Pro- and Anti-Inflammatory Mediators in Rat Dural Immune Cells.

Authors:  Lisa A McIlvried; Lisa A Borghesi; Michael S Gold
Journal:  Headache       Date:  2015-06-30       Impact factor: 5.887

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction.

Authors:  Michael M Dowling; Michael J Noetzel; Mark J Rodeghier; Charles T Quinn; Deborah G Hirtz; Rebecca N Ichord; Janet L Kwiatkowski; E Steven Roach; Fenella J Kirkham; James F Casella; Michael R DeBaun
Journal:  J Pediatr       Date:  2014-02-13       Impact factor: 4.406

10.  Sex-, stress-, and sympathetic post-ganglionic-dependent changes in identity and proportions of immune cells in the dura.

Authors:  Lisa A McIlvried; J Agustin Cruz; Lisa A Borghesi; Michael S Gold
Journal:  Cephalalgia       Date:  2016-07-11       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.